- Home
- CPSS vs PLX Comparison
CPSS vs PLX Comparison
Compare CPSS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPSS
- PLX
- Stock Information
- Founded
- CPSS 1991
- PLX 1993
- Country
- CPSS United States
- PLX United States
- Employees
- CPSS N/A
- PLX N/A
- Industry
- CPSS Finance: Consumer Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPSS Finance
- PLX Health Care
- Exchange
- CPSS Nasdaq
- PLX Nasdaq
- Market Cap
- CPSS 193.8M
- PLX 122.6M
- IPO Year
- CPSS 1992
- PLX 1998
- Fundamental
- Price
- CPSS $10.01
- PLX $1.54
- Analyst Decision
- CPSS
- PLX Strong Buy
- Analyst Count
- CPSS 0
- PLX 1
- Target Price
- CPSS N/A
- PLX $15.00
- AVG Volume (30 Days)
- CPSS 24.3K
- PLX 1.2M
- Earning Date
- CPSS 07-29-2025
- PLX 08-13-2025
- Dividend Yield
- CPSS N/A
- PLX N/A
- EPS Growth
- CPSS N/A
- PLX N/A
- EPS
- CPSS 0.79
- PLX 0.05
- Revenue
- CPSS $188,776,000.00
- PLX $59,764,000.00
- Revenue This Year
- CPSS $146.82
- PLX $65.02
- Revenue Next Year
- CPSS $18.24
- PLX $57.34
- P/E Ratio
- CPSS $12.67
- PLX $31.98
- Revenue Growth
- CPSS N/A
- PLX 0.18
- 52 Week Low
- CPSS $7.99
- PLX $0.82
- 52 Week High
- CPSS $12.73
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CPSS 58.65
- PLX 47.41
- Support Level
- CPSS $9.75
- PLX $1.32
- Resistance Level
- CPSS $10.21
- PLX $1.67
- Average True Range (ATR)
- CPSS 0.30
- PLX 0.11
- MACD
- CPSS 0.00
- PLX 0.04
- Stochastic Oscillator
- CPSS 65.57
- PLX 62.86
About CPSS Consumer Portfolio Services Inc.
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.